Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.
Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L, Wang L, Wang Y, Bouillaud E, Brown DM. Wykoff CC, et al. Among authors: wachtlin j. Am J Ophthalmol. 2024 Apr;260:70-83. doi: 10.1016/j.ajo.2023.07.012. Epub 2023 Jul 15. Am J Ophthalmol. 2024. PMID: 37460036 Free article. Clinical Trial.
Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS.
Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, Kahl M, Sachs H, Schilling H, Thelen U, Wiedemann P, Wachtlin J; Prospective Noninterventional Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients with Neovascular Age-Related Macular Degeneration Study Group. Framme C, et al. Among authors: wachtlin j. Ophthalmol Retina. 2018 Jun;2(6):539-549. doi: 10.1016/j.oret.2017.09.017. Epub 2017 Nov 20. Ophthalmol Retina. 2018. PMID: 31047606
Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Wachtlin J, Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wiedemann P, Framme C. Wachtlin J, et al. Graefes Arch Clin Exp Ophthalmol. 2021 Mar;259(3):601-611. doi: 10.1007/s00417-020-04803-8. Epub 2020 Aug 13. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 32789651 Free PMC article.
PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.
Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wachtlin J, Wiedemann P, Framme C; PERSEUS Study Group. Eter N, et al. Among authors: wachtlin j. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2213-2223. doi: 10.1007/s00417-021-05073-8. Epub 2021 Feb 6. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 33547967 Free PMC article.
See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment.
Enders C, Duncker T, Schürks M, Scholz P, Dörner J, Müller C, Wachtlin J, Lommatzsch A. Enders C, et al. Among authors: wachtlin j. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1563-1570. doi: 10.1007/s00417-022-05942-w. Epub 2022 Dec 23. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36562802 Free PMC article.
72 results